Through molecular dynamics analyses, ertapenem and oxymetholone were identified as the most stable complexes, exhibiting minimal root-mean-square deviation fluctuations and maintaining hydrogen-bond networks similar to that of the reference inhibitor osimertinib.<h4>Conclusion</h4>These findings suggest that ertapenem and oxymetholone are promising structurally unique scaffolds for targeting osimertinib-resistant EGFR C797S-driven NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.